Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

AxdAdB3-F/RGD (#RDB03012)

Recombinant Adenovirus Expressing Mutant E1A

Clone info. Recombinant Adenovirus Expressing Mutant E1A.
Vector backbone pL-dAdB3 (Adenovirus)
Growth remarks 5 percent FCS is fine.
Gene/insert name AdV_5 E1A cDNA
Depositor|Developer Hamada, Hirofumi |
 
Additional map

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested.(Clin. Cancer Res., 13, 3043-3050 (2007).) In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
遺伝子組換え生物の受入れ確認書 [Word]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 非営利機関の非営利学術研究へ提供する。利用者が本件リソースを利用した研究成果に基づき特許申請、商業活動等を行う場合は、利用者は事前に寄託者に連絡する。利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Clin. Cancer Res., 13, 3043-3050 (2007).)。利用者は、研究成果の公表にあたって謝辞の表明を必要とする。
備考 【追加提供依頼書】受入れ確認書(書式J)
作出したウイルスは大臣確認実験となる。
組換え体提供にかかる書式が必要です。

Catalog # Resource name Availability Shipping form Fee (non-profit org.)
RDB03012 AxdAdB3-F/RGD Under QC test. Please contact us. Virus, lysate of infected cell culture JPY 32,340 plus cost of shipping containers, dry ice (if required) and shipping charge

check Please wait for results of QC test to be uploaded. This clone will be sequenced a portion for examination.

How to cite this biological resource

Materials & Methods section:

The AxdAdB3-F/RGD was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB03012).

Reference section:

Wakayama M., Abei M., Kawashima R., Seo E., Fukuda K., Ugai H., Murata T., Tanaka N., Hyodo I., Hamada H., Yokoyama K.K., E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers. Clin. Cancer Res., 13, 3043-3050 (2007). PMID 17505007. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

check Please wait for results of QC test to be uploaded. This clone will be sequenced a portion for examination.

References

Original, user report and related articles

original Wakayama M., E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers. Clin. Cancer Res., 13, 3043-3050 (2007). PMID 17505007. [link to RRC of NBRP]
user_report Shen, Y.H., Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in Mice. PLoS One. 11 (1): e0147173 (2016). PMID 26799485. [link to RRC of NBRP]
user_report Wang, H., Enhanced Antitumor Efficacy of Integrin-targeted Oncolytic Adenovirus AxdAdB3-F/RGD on Bladder Cancer. Urology, pii: S0090-4295(13) 01369-1 (2013). PMID 24315309. [link to RRC of NBRP]